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ABSTRACT 
Background: Postoperative blood hyperlactaemia is an indicator of organ anaerobic metabolism and is associated with 
morbidity after cardiac surgery. This prospective study aims to explore the source, triggers and clinical implications for 
hyperlactaemia in patients undergoing mitral valve surgery using Custodiol cardioplegia. Methods: Twenty consecutive 
elective patients undergoing open-heart surgery for mitral valve repair/replacement using Custodiol (based on Bret- 
schneider’s HTK-solution) cardioplegia were recruited. A serial measurement of arterial blood lactate was performed. 
Pre-, intra- and post-operative clinical data were obtained and cardiac injury was determined by serial plasma measure- 
ment of postoperative release of CK-MB. Results: There were no in-hospital deaths. Most of the patients (n = 16) need- 
ed intraoperative direct current cardioversion to treat ventricular arrhythmias or post-operative vasopressors (n = 13) to 
treat vasoplegia. There was significant cardiac injury as determined by the marked increase of serum CK-MB (p < 0.05). 
A significant (p < 0.05) increase in blood lactate was found to follow a biphasic profile. The first peak (from 0.54 ± 
0.03 to 1.3 ± 0.07 mM) was observed immediately following the release of the aortic cross-clamp and remained high for 
1 hour. This was followed by a second peak at 12 hours postoperatively (1.9 ± 0.2 mM). The second rise in lactate was 
seen only in patients that required post-operative vasopressors (1.3 ± 0.2 vs 2.2 ± 0.3 mM, p < 0.05), in whom a signifi- 
cant late decrease in CVP was also observed (12.2 ± 1.0 to 7.7 ± 1.0 for 1 and 12 hours postoperative, respectively). 
Hyperlactaemia did not correlate with any other variables including CK-MB levels, cross-clamp or cardiopulmonary 
bypass time. Conclusions: In patients undergoing mitral valve surgery with Custodiol cardioplegia there is marked car- 
diac injury and a biphasic release of blood lactate. The initial peak in lactate occurs immediately following unclamping 
the aorta and is likely to be of organ (e.g. heart and lungs) origin. A second peak is only seen in patients requiring post- 
operative vasopressors to treat vasoplegia. Hyperlactaemia following mitral valve surgery with Custodiol cardioplegia 
does not seem to be related to myocardial injury as expressed by CK-MB release. 
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1. Introduction 
Cardioplegic arrest (CA) and cardiopulmonary bypass 
(CPB) during cardiac surgery are associated with ische- 
mic/hypoxic stress seen in cardiac and non-cardiac tissue. 
Cross-clamping the aorta and infusion of cardioplegic 
solutions render the heart (and the lungs) ischemic [1-3]. 
The addition of large volume of pump prime to the pa- 
tient’s circulation at the beginning of CPB decreases ar- 
terial oxygen content causing the release vasoconstric- 
tors and therefore results in reduced oxygen delivery to 
peripheral (e.g. skeletal muscle) and visceral (e.g. GI  
tract) tissues [4-6]. In skeletal muscle the effect of CPB 
involves changes in metabolic activity as well as changes 
in blood flow [7,8]. A consequence of ischemic/hypoxic 
stress (anaerobic metabolism) associated with CA and 
CPB is the accumulation of lactate in cardiac [9,10] as 
well as in peripheral (skeletal muscle) and visceral tissue 
[11]. Significant proportion of the lactate accumulated in 
tissue effluxes using the lactate transporter [12]. There- 
fore measurement of blood lactate levels is used to de- 
termine the extent of anaerobic metabolism and indi- 
rectly infer the extent of tissue oxygenation/perfusion.  
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However, the interpretation of elevated blood lactate 
levels following cardiac surgery is complex as the levels 
are altered by amongst other factors inter-organ substrate 
flux, hepatic lactate uptake, hypovolemia, low cardiac 
output (LCO), peripheral arterial thrombosis) [13]. Evi- 
dence suggests that elevated blood lactate levels (hyper- 
lactaemia) observed following cardiac surgery may cor- 
relate with the duration of CPB [14], it is relatively fre- 
quent and is associated with an increased postoperative 
morbidity [15,16]. There is little knowledge about chan- 
ges in blood lactate during and after mitral valve surgery 
using Custodiol (Bretschneider’s histidine-tryptophan- 
ketoglutarate) cardioplegia. This cardioplegia is suppo- 
sed to provide good buffering capacity and enhances ana- 
erobic energy production during ischaemic cardioplegic 
arrest [17,18]. Cardioplegic solutions are likely to have 
different systemic effects due to their composition and 
the difference in their volume. In this prospective pilot 
study we aim to explore the potential source, triggers and 
clinical implications for hyperlactaemia in patients with 
mitral valve disease undergoing mitral valve surgery us- 
ing Custodiol cardioplegia. 
2. Materials and Methods 
A consecutive series of adult patients with mitral valve 
disease undergoing elective mitral valve repair/replace- 
ment were prospectively recruited. The study was ap- 
proved by the Hospital Ethics Committee, and all pa- 
tients gave informed consent. 
2.1. Surgical and Anesthetic Techniques 
A standard CPB circuit was used with a 40-µm filter, a 
Stockert roller pump and a fibre membrane oxygenator 
(Dideco, Sorin, Cobe). Priming solution included 1000 
mL of balanced electrolyte solution (pH 7.4), 500 mL 
plasma expanding reagent (6% hydroxyethyl starch), 100 
mL 18% mannitol, and 5000 IU Heparin. Non-pulsatile 
flow was used at a rate of 2.4 l/m2/min. Systemic tem0 
perature was kept at 34˚C. Heparin IV was used at a dose 
of 300 UI/Kg to achieve a target ACT of 480 sec or more. 
For induction and maintenance of anesthesia, Propofol 
infusion was used at 2 - 2.8 µg/ml (5.4 - 7.5 mg/Kg/min) 
combined with Remifentanyl infusion at 3.5 - 7.60 μg/ml 
(0.13 - 0.28 µg/Kg/min) using a Diprifusor pump. Neu- 
romuscular blockade was achieved with 0.6 mg/Kg of 
Rocuronium infused at 0.12 mg/Kg/min. Normocapnia 
was maintained and the lungs were ventilated with a 
mixture of air/O2 = 0.5, with low flow ventilation tech- 
nique. Target mean arterial blood pressure was 65 - 70 
mmHg. On removal of the aortic cross clamp the need 
for direct current (DC) cardioversion was dictated by the 
occurrence of malignant ventricular arrhythmias. Fol-  
lowing transfer to intensive care unit sedation was main- 
tained with Propofol infusion at 1 - 2 μg/ml combined 
with Remifentanyl infusion at 2.0 - 2.5 μg/ml. Weaning 
from mechanical ventilator was according to a predefined 
protocol. Adequate postoperative systemic perfusion was 
achieved by aiming for a mean blood pressure of 65 
mmHg or more. Volemia was maintained with fluid re- 
suscitation targeting a central venous pressure (CVP) of 
12 - 15 mmHg for ventilated patients and 8 - 12 mmHg 
for non-ventilated patients. The occurrence of hypoten- 
sion (without sepsis) despite adequate fluid resuscitation, 
together with evidence of perfusion abnormalities (i.e. 
oliguria) was regarded as vasoplegia. This was treated 
with the vasopressor of choice Noradrenaline (dosages 
range 0.02 - 1.5 mcg/kg/min). Occurrence of low cardiac 
output (LCO) was treated with Dopamine (dosage range 
5 - 20 mcg/kg/min) or Enoximone (4 µg/kg/min). 
2.2. Cardioplegic Techniques 
A single shot ice-cold Custodiol cardioplegia was de- 
livered directly in the aortic root for approximately 10 
min at a rate of 200 ml/min giving a mean total infusion 
volume of 2000 ml. 
2.3. Blood Lactate 
This was assessed serially by measuring plasma lactate 
levels at baseline (pre-op), intraoperatively (at aortic 
cross clamp release and at 30 minutes of reperfusion), 
and postoperatively (at 1, 6, 12, 24 and 48 hours). 
2.4. Myocardial Injury 
Serial release of Creatine Kinase (CK-MB) was used as a 
marker of myocardial injury. For this purpose blood sam- 
ples were collected from the radial artery line at 1, 6, 12, 
24 and 48 hours postoperatively. 
2.5. Generic In-Hospital Outcome 
A full set of in-hospital outcomes were monitored. These 
also included generic postoperative complications such 
as myocardial infarction, low cardiac output syndrome, 
need for vasopressors and/or inotropic support, arrhyth- 
mia, ST changes, renal, respiratory, and neurological 
complications, total fluid balance, total blood loss, trans- 
fusion requirement, ventilation time, length of intensive 
care and hospital stay. 
2.6. Management of Pre-Operative Medications 
Preoperative medications including α-blockers, diuretics, 
anti-hypertensives, and calcium channel blockers were 
routinely omitted on the day of surgery. ACE-inhibitors 
were withdrawn on the evening before the operation. 
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2.7. Statistical Analysis 
Data were expressed as mean ± standard error (SE). 
Comparison between continuous variables for paired 
groups was made using a non-parametric test (Wil- 
coxon’s signed rank test). Comparison between nominal 
variables was made using Chi Square test and signifi- 
cance determined using Fisher’s exact test. Correlation 
coefficient was calculated and significance determined 
by use of Fisher’s r to z. All statistical analyses men- 
tioned were performed with the aid of a computerized 
software package, Statview for Windows (SAS Institute 
Inc., Cary, NC, USA). 
3. Results 
3.1. Clinical Outcome 
Preoperative patients’ demographics are shown in Table 
1. 
Key intra- and postoperative data are shown in Table 
2. 
There were neither in-hospital deaths nor major neu- 
rological, respiratory, renal, and gastrointestinal compli-  
 
Table 1. Preoperative data. 
Variable Total number (n = 20) 
Male/Female 15/5 
Age (years) 53 ± 3 
BSA (m2) 1.89 ± 0.04 
Hypertension 9 
Ejection fraction (%)  64 ± 1 
NYHA class   
I  6 
II  13 
III 1 
History of AF  2 
History of heart failure  2 
Degree of MR  
3+/4 11 
4+/4 9 




Associated procedures  
Tricuspid valve repair 6 
AF ablation 1 
Data are presented as mean ± SE or as number of patients. BSA, body sur- 
face area; AF, atrial fibrillation; MV, mitral valve; NYHA, New York Heart 
Association; CPB, cardiopulmonary bypass; ICU, intensive care unit. 
cations. No episodes of low cardiac output or myocardial 
infarction were observed. Sixteen patients (80%) re- 
quired intra-operative DC cardioversion on releasing the 
aortic cross-clamp due to ventricular arrhythmias. Thir- 
teen patients (65%) suffered postoperative vasoplegia 
according to predefined criteria and required usage of 
vasopressors. 
3.2. Cardiac Injury 
There was significant cardiac injury as determined by the 
marked increase of serum CK-MB after surgery (Figure 
1(A)). 
It has been suggested that CK-MB levels of more than 
100 ng/ml has 95% specificity in relation to cardiac 
events whilst 45 ng/ml has 76% specificity [19]. Peak 
CK-MB at >45 ng/ml was seen in 19 patients whilst only 
2 had levels >100 ng/ml. These levels were seen on aver- 
age at 1, 6 and 12 hours postoperatively. Release of 
CK-MB did not correlate with the need for intraoperative 
DC cardioversion or need for postoperative vasopressors 
(Figures 1(B) and (C)). 
3.3. Release of Blood Lactate 
A time dependent increase in blood lactate was seen 
immediately following release of aortic cross clamp and 
remained elevated at 48 hours postoperatively compared 
to pre-operative levels (Figure 2). The increase in blood 
lactate was found to follow a biphasic profile. The first 
peak was sharp and occurred soon after the release of the 
aortic cross clamp, remaining high for the following 30 - 
 
Table 2. Intra and post-operative data. 
Variable n = 20 
CPB time (min) 127 ± 6 
Cross-clamp time (min) 109 ± 5 
ICU stay (hours) 50 ± 7 
Hospital stay (days) 12.6 ± 2.6 
Intra-operative DC cardioversion 16 
Sinus rhythm on weaning from CPB  18 
Inotropic support on weaning from bypass 7 
Postoperative arrhythmia  8 
Total blood loss (ml) 1051 ± 145 
ST elevation in ICU 1 
Temporary pacing in ICU 1 
Use of vasopressors (noradrenaline) in ICU 13 
Ventilation time (hours) 13.7 ± 3.3 
Blood loss (ml) 1077 ± 150 
% Ejection fraction (5th day) 63 ± 2 
Data are presented as mean ± SE or as number of patients. CPB, cardio- 
pulmonary bypass; ICU, intensive care unit; DC, direct current. 
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60 minutes. This was followed by a further slow rise in 
blood lactate that peaked at 12 hours postoperatively. 
However, even at 48 hours postoperatively, the lactate 




Figure 1. Cardiac injury (postoperative CK-MB release) in 
patients undergoing mitral valve surgery. Data are pre- 
sented as mean ± SE for CK-MB levels for all patients (A) 
and comparing the effect of DC cardioversion (B) and use 
of vasopressors during ICU stay (C). 
 
 
Figure 2. Time-dependent increase in blood lactate during 
surgery. A significant increase in blood lactate was seen im- 
mediately following the release of aortic cross clamp. A sec- 
ond slow rise in blood lactate was seen after 1 hour reperfu- 
sion. Data are presented as mean ± SE. *vs basal blood lev- 
els; **vs basal and 1 hour levels. 
3.4. Early Phase of Hyperlactatemia and  
Myocardial Ischemic Stress/Injury 
There was no correlation between blood lactate levels 
and cardioplegic arrest time as shown in Figure 3(A). 
This was also confirmed when aortic cross-clamp time 
was correlated with the actual increase in lactate at each 
time point (data not shown). The finding that cardio- 
plegic arrest time did not correlate with blood lactate 
levels is consistent with the finding that cardiac injury 
(peak CK-MB levels) also did not correlate with early 
elevation in lactate (Figure 3(B)). None of the other pre- 
intra- or post-operative clinical measurements including 
intraoperative DC cardioversion , need for postoperative 
vasopressors, arrhythmia, need for pacing, blood loss, 
ventilation time, ICU stay or hospital stay correlated with 
the early peak of lactate. 
3.5. Delayed Phase of Blood Hyperlactaemia and  
Post-Operative Vasoplegia 
We found a strong correlation between the late second 
slow rise in blood lactate and the post-operative use of 
vasopressors (Figure 4). This relationship was further 
observed when using lactate value of 1.4 mM as a cut off 
 
 
Figure 3. Scattergrams showing the relationship between 
lactate levels at 0, 0.5 and 1 hour against cross-clamp time 
(A) and cardiac injury (B). 
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Figure 4. Changes in blood lactate during surgery measured 
in patients with or without use of vasopressors during ICU 
stay. Data are presented as mean ± SE. *vs values for ino- 
tropic support at the corresponding time. 
 
(approximately separating the slow and the delayed 
phase). This approach showed that lactate levels > 1.4 
mM occurred particularly in patients in whom the need 
for vasopressors was prolonged (Figure 5(A)). 
In addition, in patients with prolonged postoperative 
need for vasopressor the values of CVP were signifi- 
cantly lower in correspondence of the late phase of hy- 
perlactaemia despite adequate volume replacement (Fig- 
ure 6). On the contrary, there was no relationship be- 
tween the late peak of blood lactate and other parameters 
including cross-clamp and CPB time or CK-MB release 
(Figure 5(B)). In addition, there was a trend for an asso- 
ciation (not significant) between levels of plasma lactate 
and changes in volemia due to either blood loss or total 
fluid balance (24 hr) (Figures 7(c) and (d)). 
4. Discussion 
This work reports novel findings highlighting the re- 
lationship between levels of blood lactaemia, cardiac 
injury (as expressed by release of CK-MB) and clinical 
outcome in elective patients undergoing mitral valve 
surgery using Custodiol cardioplegia. It suggests that a 
significant increase in blood lactate is seen immediately 
upon release of aortic cross-clamp and this level is main- 
tained for up to 48 hours postoperatively. Of note, a late 
slow increase in blood lactate that peaked at 12 hours 
after surgery was only observed in patients requiring 
postoperative vasopressors to treat vasoplegia. However, 
the increase in blood lactate at all-time points did not 
correlate with myocardial injury or other measured cli- 
nical outcome parameters. 
The early phase increase in plasma lactate is likely to 
 
Figure 5. Duration of vasopressor support in ICU (A) or 
CPB, cross-clamp time and cardiac injury (CK-MB release) 
(B) divided into patients that had high or low lactate meas- 
ured at 12 hours postoperatively. Data are presented as 
mean ± SE. *vs high lactate levels. 
 
be due in part to myocardial (and probably pulmonary) 
lactate that had accumulated during the cardioplegic ar- 
rest and CPB. Detrimental effects of CPB and CA are 
potential sources of lactate release during early phase of 
hyperlactatemia. During CA, the heart is rendered ische- 
mic where anaerobic metabolism (and lactate production) 
becomes the main source of energy production. Accu- 
mulated lactate is known to efflux the heart (with H+) 
immediately following reperfusion [12]. Work using mi- 
crodialysis has demonstrated that during cardioplegic 
arrest and CPB the heart accumulates lactate in the vas- 
culature [9,10]. Lactate accumulated in heart cells during 
ischemia is known to be released immediately following 
upon reperfusion [12]. Since the heart is highly metab- 
olically active it is likely to be the main organ sustaining 
ischemic stress during CPB and cardioplegic arrest. 
However, since our study suggests that plasma lactate 
levels are maintained for a further 1 hour, other organs 
would also contribute likely by suffering ischemia during 
CPB. 
Our study suggests that the use of Custodiol cardio- 
plegia in patients undergoing mitral valve surgery is as- 
sociated with significant myocardial injury. However, the 
finding that plasma lactate levels immediately following 
unclamping the aorta do not correlate with cardiac injury 
as expressed by CK-MB release is potentially surprising.  
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Figure 6. Changes in CVP divided according to require- 
ment of vasopressors in ICU. Data are presented as mean ± 
SE. *vs corresponding CVP measured at 1 hr. 
 
In our opinion this could be due to the fact that cross- 
clamp time was relatively long as most of the patients (n 
= 17) had cross-clamp time between ~90 - 140 min. Al- 
ternatively, this could simply reflect the fact that follow- 
ing an acute cardiac ischemic event it takes much longer 
for the CK-MB levels to rise in the plasma compared to 
the time required for the plasma lactate. Furthermore, 
while the levels of lactate are directly linked to ischemia, 
the release of CK-MK in patients undergoing mitral val- 
ve surgery might also reflect the specific need of entering 
the left atrium via a long incision across its muscular 
wall (direct iatrogenic injury) to operate on the mitral 
valve (plus a further incision of the right atrial wall for 
those undergoing concomitant tricuspid valve repair). 
This could lead to an extra release of CK-MB over and 
above that associated with cardioplegic arrest related in- 
jury. The latter point might also explain why in our study 
cardiac injury as expressed by CK-MB plasma levels did 
not correlate with aortic cross-clamp time (cardiac ische- 
mia). Of note, other perioperative interventions (e.g. in- 
traoperative DC cardioversion) did not alter level of plas- 
ma lactate suggesting that the increase is most likely due 
entirely to the long period of ischemic cardioplegic ar- 
rest. 
Of interest, this study also show for the first time that 
the increase in blood lactate in patients undergoing mitral 
valve surgery with Custodiol cardioplegia follows a bi- 
phasic profile (early and sharp first peak followed by a 
late and slow secondary peak) where the late slow in- 
crease was only seen in patients needing postoperative 
vasopressors, which might have implications for their 
effective management. We noted that in these patients  
 
Figure 7. (a) shows the individual values for CVP in indi- 
vidual patients divided into high or low lactate levels whilst; 
(b) shows the same data presented as mean ± SE. Blood loss 
(closed circle) and total fluid balance (24 hr) levels in indi- 
vidual patients divided into high or low lactate levels (c); 
Same data is shown as mean ± SE (d). 
 
the late second peak of blood lactate did not correlate 
with late levels of CK-MB and it reached its highest 
value at 12 hours postoperatively. 
It remains uncertain whether this late slow rise in lac- 
tate is due to CPB-induced tissue metabolic stress or due 
to side effects of vasopressors or both. We feel that our 
study is too small to answer this important question. 
However, when looking at the literature, it is evident that 
the significance, source and clinical implications of 
changes in blood lactate levels during cardiac surgery 
remain still unresolved. Elevated levels of blood lactate 
have been observed also following off-pump coronary 
artery bypass grafting, although to less extent than the 
conventional coronary surgery with CPB (CABG) [20]. 
Others have suggested that hypothermia, particularly in 
skeletal muscles, could be triggering lactate release in 
these patients [21]. Postoperative lactate release has been 
shown by others to be affected by degree and type of 
vasoconstrictor and/or inotropic support. The use of beta- 
blockade peri-operatively in the presence of phenyle- 
phrine as vasopressor did not alter arterial lactate up to 
16 hours post operatively [22]. Furthermore, in patients 
undergoing CABG only the use of noradrenaline but not 
milrinone triggered increase in blood lactate during sur- 
gery [23]. 
In our practice, we used the vasopressor noradrenaline 
in accordance with the accepted practice of maintaining  
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adequate systemic perfusion (aiming for a mean blood 
pressure of 65 mmHg or above). The use of noradrena- 
line was prompted by the occurrence of hypotension 
(without sepsis) despite adequate fluid resuscitation, to- 
gether with evidence of perfusion abnormalities (i.e. 
oliguria). This condition is regarded by many as vasople- 
gic syndrome [24]. Noradrenaline is known to produce a 
dose-dependent increase in systemic vascular resistance. 
Although the drug can stimulate cardiac b-receptors over 
a wide range, the cardiac output is increased only at low 
doses. At high dose rates, the cardiac output decreases in 
response to the vasoconstriction and increased afterload. 
Hence, the administration of any vasoconstrictor agent 
carries a risk of hypoperfusion and ischemia involving 
any tissue bed or vital organ. It might be therefore that 
the observed late slow late peak in blood lactate in our 
study is related to excessive systemic vasoconstriction. 
Naturally, for any condition that requires vasoconstrictor 
drugs to maintain a blood pressure, it is difficult to dis- 
tinguish adverse drug effects and adverse disease effects 
with potentially subsequent little or no room for thera- 
peutic manipulations. Of note, thirteen patients (65%) in 
our study appeared to suffer vasoplegia during the post- 
operative stay since they required a prolonged use of 
noradrenaline for more than 5 hours despite normal car- 
diac output status. One might argue that the use of Cus- 
todiol in our study could have triggered this vasoplegia- 
type condition leading to the observed degree of systemic 
anaerobic metabolism. Vasoplegic syndrome is a well- 
described form of vasodilatory shock that potentially can 
occur after separation from CPB [24]. It is a state of low 
systemic arterial pressure despite high cardiac output and 
adequate fluid resuscitation characterized by markedly 
low systemic vascular resistance [25]. The reported inci- 
dence ranges from 9% to 44%, yet the origin has not 
been completely elucidated [24]. There are already re- 
ports of vascular complications associated with the use of 
Custodiol. These include low efficacy at protecting hu- 
man and pig liver endothelial cells [26,27] and ability to 
induce red blood cell deformability possibly by altering 
cell membrane [28]. In keeping with this evidence, our 
findings appear to support the notion that Custodiol car- 
dioplegia might be associated with a postoperative vaso- 
plegic syndrome, however larger studies are required to 
ascertain the risk/benefit balance of using Custodiol car- 
dioplegia in patients undergoing mitral valve surgery. 
In conclusion, this study suggests that there might be a 
significant degree of myocardial injury associated with 
the use of Custodiol cardioplegia in patients undergoing 
mitral valve surgery. In addition, there appear to be a 
biphasic release of blood lactate with an initial peak oc- 
curring immediately following unclamping the aorta and 
likely to be of organ (e.g. heart and lungs) origin. A sec- 
ond peak is only seen in patients requiring postoperative 
vasopressors to treat a vasoplegic-type of syndrome. Hy- 
perlactaemia following mitral valve surgery with Custo- 
diol cardioplegia does not seem to be related to myocar- 
dial injury as expressed by CK-MB release. Larger stud- 
ies are warranted to confirm these findings. 
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